师树田,聂绍平

• 1:首都医科大学附属北京安贞医院急诊危重症中心

摘要(Abstract)：

<正>急性冠状动脉综合征(ACS)是一组由急性心肌缺血引起的临床综合征,包括急性心肌梗死(AMI)及不稳定型心绞痛(UA),其中AMI又分为ST段抬高心肌梗死(STEMI)和非ST段抬高心肌梗死(NSTEMI)。美国、欧洲以及中国现行ACS管理指南及经皮冠状动脉介入治疗(PCI)指南均推荐阿司匹林联合一种P2Y12受体拮抗剂的

关键词(KeyWords)： 替格瑞洛;P2Y12受体拮抗剂

Abstract:

Keywords:

基金项目(Foundation): 北京市自然科学基金(7141003);; 国家自然科学基金(81270284)

作者(Author): 师树田,聂绍平

参考文献(References)：

• [1]Husted S,van Giezen JJ.Ticagrelor:the first reversibly binding oral P2Y12 receptor antagonist.Cardiovasc Ther,2009,27:259-274.
• [2]Ramaraj R,Movahed MR,Hashemzadeh M.Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome.J Interv Cardiol,2011,24:199-207.
• [3]Abergel E,Nikolsky E.Ticagrelor:an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.Vasc Health Risk Manag,2010,6:963-977.
• [4]Gurbel PA,Bliden KP,Butler K,et al.Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease:the ONSET/OFFSET study.Circulation,2009,120:2577-2585.
• [5]Lombo B,Diez JG.Ticagrelor:the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes.Core Evid,2011,6:31-42.
• [6]马依彤,谢翔.血小板功能和基因检测指导下的抗血小板治疗进展.中国介入心脏病学杂志,2014,22:44-47.
• [7]Nawarskas JJ,Snowden SS.Critical appraisal of ticagrelor in the management of acute coronary syndrome.Ther Clin Risk Manag,2011,7:473-488.
• [8]Tantry US,Bliden KP,Gurbel PA.Azd6140.Expert Opin Investig Drugs,2007,16:225-229.
• [9]Husted S,Emanuelsson H,Heptinstall S,et al.Pharmacodynamics,pharmacokinetics,and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis:a doubleblind comparison to clopidogrel with aspirin.Eur Heart J,2006,27:1038-1047.
• [10]Cannon CP,Husted S,Harrington RA,et al.Safety,tolerability,and initial efficacy of azd6140,the first reversible oral adenosine diphosphate receptor antagonist,compared with clopidogrel,in patients with non-ST-segment elevation acute coronary syndrome:Primary results of the DISPERSE-2 trial.J Am Coll Cardiol,2007,50:1844-1851.
• [11]Gurbel PA,Bliden KP,Butler K,et al.Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies:the RESPOND study.Circulation,2010,121:1188-1199.
• [12]Husted SE,Storey RF,Bliden K,et al.Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease:results from the ONSET-OFFSET and RESPOND studies.Clin Pharmacokinet,2012,51:397-409.
• [13]Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med,2009,361:1045-1057.
• [14]Quinlan DJ,Eikelboom JW,Goodman SG,et al.Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes.Eur Heart J,2011,32:2256-2265.
• [15]Cannon CP,Harrington RA,James S,et al.Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes(PLATO):a randomised double-blind study.Lancet,2010,375:283-293.
• [16]James SK,Roe MT,Cannon CP,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management:substudy from prospective randomised PLATelet inhibition and patient Outcomes(PLATO)trial.BMJ,2011,342:d3527.
• [17]Steg PG,James S,Harrington RA,et al.Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention:A Platelet Inhibition and Patient Outcomes(PLATO)trial subgroup analysis.Circulation,2010,122:2131-2141.
• [18]Held C,Asenblad N,Bassand JP,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery:results from the PLATO(Platelet Inhibition and Patient Outcomes)trial.J Am Coll Cardiol,2011,57:672-684.
• [19]James S,Budaj A,Aylward P,et al.Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function:results from the Platelet Inhibition and Patient Outcomes(PLATO)trial.Circulation,2010,122:1056-1067.
• [20]Husted S,James S,Becker RC,et al.Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes:a substudy from the prospective randomized PLATelet inhibition and patient Outcomes(PLATO)trial.Circ Cardiovasc QualOutcomes,2012,5:680-688.
• [21]James S,Angiolillo DJ,Cornel JH,et al.Ticagrelor vs.clopidogrel in patients with acute coronary syndromes and diabetes:a substudy from the PLATelet inhibition and patient Outcomes(PLATO)trial.Eur Heart J,2010,31:3006-3016.
• [22]James SK,Storey RF,Khurmi NS,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.Circulation,2012,125:2914-2921.
• [23]Cornel JH,Becker RC,Goodman SG,et al.Prior smoking status,clinical outcomes,and the comparison of ticagrelor with clopidogrel in acute coronary syndromes—Insights from the PLATelet inhibition and patient Outcomes(PLATO)trial.Am Heart J,2012,164:334-342.e1.
• [24]Alexopoulos D,Xanthopoulou I,Gkizas V,et al.Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.Circ Cardiovasc Interv,2012,5:797-804.
• [25]Parodi G,Valenti R,Bellandi B,et al.Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients:RAPID(Rapid Activity of Platelet Inhibitor Drugs)primary PCI study.J Am Coll Cardiol,2013,61:1601-1606.
• [26]Navarese EP,Buffon A,Kozinski M,et al.A critical overview on ticagrelor in acute coronary syndromes.QJM,2013,106:105-115.
• [27]Wittfeldt A,Emanuelsson H,Brandrup-Wognsen G,et al.Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans.J Am Coll Cardiol,2013,61:723-727.
• [28]Scirica BM,Cannon CP,Emanuelsson H,et al.The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO(Platelet Inhibition and Patient Outcomes)trial:results of the continuous electrocardiographic assessment substudy.J Am Coll Cardiol,2011,57:1908-1916.
• [29]Henriksson M,Janzon M.Cost-effectiveness of ticagrelor in acute coronary syndromes.Expert Rev Pharmacoecon Outcomes Res,2013,13:9-18.
• [30]何江江,张崖冰,高润霖,等.替格瑞洛与氯吡格雷治疗急性冠脉综合征的药物经济学分析.中国药物经济学,2013,3:27-32.
• [31]Wijns W,Kolh P,Danchin N,et al.Guidelines on myocardial revascularization.Eur Heart J,2010,31:2501-2555.
• [32]Hamm CW,Bassand JP,Agewall S,et al.ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:The Task Force for the management of acute coronary syndromes(ACS)in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC).Eur Heart J,2011,32:2999-3054.
• [33]Steg PG,James SK,Atar D,et al.ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.Eur Heart J,2012,33:2569-2619.